A retrospective study analyzing outcomes of ET in combination with CDK4/6is, everolimus or alpelisib in metastatic breast cancer
Latest Information Update: 01 Jul 2022
At a glance
- Drugs Alpelisib (Primary) ; Everolimus (Primary) ; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
- Indications Adenocarcinoma; Advanced breast cancer; Ductal carcinoma; Ductal lobular and medullary neoplasms
- Focus Therapeutic Use
Most Recent Events
- 01 Jul 2022 New trial record
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology